Literature DB >> 35022809

Idiopathic inflammatory myopathies: CT characteristics of interstitial lung disease and their association(s) with myositis-specific autoantibodies.

Amandine Laporte1, Kubéraka Mariampillai2, Yves Allenbach2,3, Nicoletta Pasi1, Victoria Donciu4, Dan Toledano1, Benjamin Granger5, Olivier Benveniste2,3, Philippe A Grenier6, Samia Boussouar7.   

Abstract

OBJECTIVES: Interstitial lung disease (ILD), one of the most common extramuscular manifestations of idiopathic inflammatory myopathies (IIMs), carries a poor prognosis. Myositis-specific autoantibody (MSA)-positivity is a key finding for IIM diagnosis. We aimed to identify IIM-associated lung patterns, evaluate potential CT-ILD finding-MSA relationships, and assess intra- and interobserver reproducibility in a large IIM population.
METHODS: All consecutive IIM patients (2003-2019) were included. Two chest radiologists retrospectively assessed all chest CT scans. Multiple correspondence and hierarchical cluster analyses of CT findings identified and characterized ILD-patient subgroups. Classification and regression-tree analyses highlighted CT-scan variables predicting three patterns. Three independent radiologists read CT scans twice to assign patients according to CT-ILD-pattern clusters.
RESULTS: Among 257 IIM patients, 94 (36.6%) had ILDs; 87 (93%) of them were MSA-positive. ILD-IIM distribution was 54 (57%) ASyS, 21 (22%) DM, 15 (16%) IMNM, and 4 (4%) IBM. Cluster analysis identified three ILD-patient subgroups. Consolidation characterized cluster 1, with significantly (p < 0.05) more frequent anti-MDA5-autoantibody-positivity. Significantly more cluster-2 patients had a reticular pattern, without cysts and with few consolidations. All cluster-3 patients had cysts and anti-PL12 autoantibodies. Clusters 2 and 3 included significantly more ASyS patients. Intraobserver concordances to classify patients into those three clusters were good-to-excellent (Cohen κ 0.64-0.81), with good interobserver reliability (Fleiss's κ 0.56).
CONCLUSION: Despite the observed IIM heterogeneity, CT-scan criteria enabled ILD assignment to the three clusters, which were associated with MSAs. Radiologist identification of those clusters could facilitate diagnostic screening and therapeutics. Interstitial lung disease in patients with idiopathic inflammatory myopathy could be classified into three clusters according to CT-scan criteria, and these clusters were significantly associated with myositis-specific autoantibodies. KEY POINTS: • Cluster analysis discerned three homogeneous groups of interstitial lung disease (ILD) for which cysts, consolidations, and reticular pattern were discriminatory, and associated with myositis-specific autoantibodies. • Like muscle- and extramuscular-specific phenotypes, myositis-specific autoantibodies are also associated with specific ILD patterns in patients with idiopathic inflammatory myopathies.
© 2021. The Author(s), under exclusive licence to European Society of Radiology.

Entities:  

Keywords:  Anti-synthetase syndrome; Cluster analysis; Idiopathic inflammatory myopathy; Interstitial lung disease; Tomography, x-ray computed

Mesh:

Substances:

Year:  2022        PMID: 35022809     DOI: 10.1007/s00330-021-08411-w

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  36 in total

Review 1.  Polymyositis and dermatomyositis (first of two parts).

Authors:  A Bohan; J B Peter
Journal:  N Engl J Med       Date:  1975-02-13       Impact factor: 91.245

2.  119th ENMC international workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10-12 October 2003, Naarden, The Netherlands.

Authors:  Jessica E Hoogendijk; Anthony A Amato; Bryan R Lecky; Ernest H Choy; Ingrid E Lundberg; Michael R Rose; Jiri Vencovsky; Marianne de Visser; Richard A Hughes
Journal:  Neuromuscul Disord       Date:  2004-05       Impact factor: 4.296

Review 3.  Polymyositis, pulmonary fibrosis and autoantibodies to aminoacyl-tRNA synthetase enzymes.

Authors:  C Marguerie; C C Bunn; H L Beynon; R M Bernstein; J M Hughes; A K So; M J Walport
Journal:  Q J Med       Date:  1990-10

Review 4.  Management of Myositis-Related Interstitial Lung Disease.

Authors:  Julie Morisset; Cheilonda Johnson; Eric Rich; Harold R Collard; Joyce S Lee
Journal:  Chest       Date:  2016-04-19       Impact factor: 9.410

Review 5.  Inclusion body myositis and myopathies.

Authors:  R C Griggs; V Askanas; S DiMauro; A Engel; G Karpati; J R Mendell; L P Rowland
Journal:  Ann Neurol       Date:  1995-11       Impact factor: 10.422

Review 6.  Advances in serological diagnostics of inflammatory myopathies.

Authors:  Olivier Benveniste; Werner Stenzel; Yves Allenbach
Journal:  Curr Opin Neurol       Date:  2016-10       Impact factor: 5.710

Review 7.  Idiopathic inflammatory myopathies and the lung.

Authors:  Jean-Christophe Lega; Quitterie Reynaud; Alexandre Belot; Nicole Fabien; Isabelle Durieu; Vincent Cottin
Journal:  Eur Respir Rev       Date:  2015-06

8.  Development of a New Classification System for Idiopathic Inflammatory Myopathies Based on Clinical Manifestations and Myositis-Specific Autoantibodies.

Authors:  Kubéraka Mariampillai; Benjamin Granger; Damien Amelin; Marguerite Guiguet; Eric Hachulla; François Maurier; Alain Meyer; Aline Tohmé; Jean-Luc Charuel; Lucile Musset; Yves Allenbach; Olivier Benveniste
Journal:  JAMA Neurol       Date:  2018-12-01       Impact factor: 18.302

Review 9.  Current Classification and Management of Inflammatory Myopathies.

Authors:  Jens Schmidt
Journal:  J Neuromuscul Dis       Date:  2018

Review 10.  Myositis-specific autoantibodies: an important tool to support diagnosis of myositis.

Authors:  Z Betteridge; N McHugh
Journal:  J Intern Med       Date:  2015-11-25       Impact factor: 8.989

View more
  1 in total

1.  Cardiovascular Risk in Myositis Patients Compared to the General Population: Preliminary Data From a Single-Center Cross-Sectional Study.

Authors:  Sabina Oreska; Hana Storkanova; Jaroslav Kudlicka; Vladimir Tuka; Ondrej Mikes; Zdislava Krupickova; Martin Satny; Eva Chytilova; Jan Kvasnicka; Maja Spiritovic; Barbora Hermankova; Petr Cesak; Marian Rybar; Karel Pavelka; Ladislav Senolt; Herman Mann; Jiri Vencovsky; Michal Vrablik; Michal Tomcik
Journal:  Front Med (Lausanne)       Date:  2022-05-03
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.